Capricor Therapeutics (NASDAQ:CAPR) Shares Up 4.8% - Time to Buy?

Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) shares shot up 4.8% during mid-day trading on Monday . The stock traded as high as $11.95 and last traded at $11.79. 1,310,184 shares changed hands during trading, a decline of 11% from the average session volume of 1,475,259 shares. The stock had previously closed at $11.25.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on CAPR. Cantor Fitzgerald restated an "overweight" rating and issued a $30.00 price target on shares of Capricor Therapeutics in a research note on Thursday, March 20th. HC Wainwright reissued a "buy" rating and issued a $77.00 target price on shares of Capricor Therapeutics in a research note on Monday, March 17th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $34.50.

Capricor Therapeutics Trading Down 1.9 %

The company has a market capitalization of $595.17 million, a P/E ratio of -12.29 and a beta of 4.65. The company has a 50 day moving average price of $12.09 and a 200 day moving average price of $14.84.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.31) by $0.15. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. The firm had revenue of $11.13 million during the quarter, compared to analysts' expectations of $9.87 million. As a group, sell-side analysts forecast that Capricor Therapeutics Inc will post -1.21 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CAPR. Summit Investment Advisors Inc. boosted its holdings in shares of Capricor Therapeutics by 54.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock worth $53,000 after acquiring an additional 1,345 shares during the period. Russell Investments Group Ltd. lifted its holdings in shares of Capricor Therapeutics by 172.8% during the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company's stock worth $64,000 after buying an additional 2,947 shares in the last quarter. Virtus ETF Advisers LLC bought a new stake in shares of Capricor Therapeutics in the fourth quarter valued at about $68,000. AlphaQuest LLC acquired a new position in shares of Capricor Therapeutics in the fourth quarter valued at about $78,000. Finally, New York State Common Retirement Fund increased its position in Capricor Therapeutics by 625.0% during the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company's stock worth $80,000 after acquiring an additional 5,000 shares during the period. Institutional investors and hedge funds own 21.68% of the company's stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.